ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2012
CD74: a potential novel target for triple-negative breast cancer.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- CD84 as a Prognostic Biomarker and Therapeutic Target in Breast Cancer: Interconnections With PDL1, CD74, and Immune Tolerance Mechanisms.Cancer genomics & proteomics · 2025Article
- Prognostic effect of CD74 and development of a radiomic model for predicting CD74 expression in non-small cell lung cancer.Frontiers in medicine · 2025Article
- Article
- The invariant chain CD74 protein is a cell surface binding partner of TIMP-1 in breast cancer cells.Molecular oncology · 2023Article
- The biomarkers related to immune infiltration to predict distant metastasis in breast cancer patients.Frontiers in genetics · 2023Article
- CD74 and HLA-DRA in Cervical Carcinogenesis: Potential Targets for Antitumour Therapy.Medicina (Kaunas, Lithuania) · 2022Article
- CD74Cancer immunology, immunotherapy : CII · 2022Article
- Article
- Therapeutic Effects of Dietary Soybean Genistein on Triple-Negative Breast Cancer via Regulation of Epigenetic Mechanisms.Nutrients · 2021Article
- Discovery and Pharmacological Evaluation of STEAP4 as a Novel Target for HER2 Overexpressing Breast Cancer.Frontiers in oncology · 2021Article
- Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments.Cells · 2020Review
- CD74 and intratumoral immune response in breast cancer.Oncotarget · 2017Article
- Lowly methylated region analysis identifies EBF1 as a potential epigenetic modifier in breast cancer.Epigenetics · 2017Article
- CD74 interacts with CD44 and enhances tumorigenesis and metastasis via RHOA-mediated cofilin phosphorylation in human breast cancer cells.Oncotarget · 2016Article
- Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell lines.Journal of cellular and molecular medicine · 2015Article
- Involvement of macrophage migration inhibitory factor and its receptor (CD74) in human breast cancer.Oncology reports · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expression status of CD74 in breast cancer stem cells and its clinical implications was evaluated in order to lay a foundation for managing breast cancer. Five hundred and eighty breast cancer specimens were enrolled in the study. The relationship between the CD74 protein and clinicopathological parameters as well as prognosis was subsequently determined. In total, 468 (80.69 %) of the 580 breast cases showed CD74-positive expression. After universal analysis, CD74 was observed to be related to lymph node metastasis and triple-negative breast cancer (P = 0.01 and 0.001). Moreover, CD74 expression has a line correlation with lymph node metastasis and triple-negative breast cancer (P = 0.02 and 0.001). Furthermore, periostin was shown to attain a significantly more distant liver metastasis and worse disease-specific survival than those with none or low-expressed CD74 protein (P = 0.001). In the Cox regression test, CD74 protein was detected as an independent prognostic factor (P = 0.001). CD74 is consistently expressed in triple-negative subgroups of breast cancer and might be a new potential marker for triple-negative breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.